1910 Genetics
1910 Genetics pioneers drug discovery by merging multimodal AI with robotic laboratory automation. This innovative approach dramatically accelerates therapeutic development for various diseases while cutting costs, transforming traditional pharmaceutical research methodologies.
Visit Website
Introduction
What is 1910 Genetics?
1910 Genetics represents a cutting-edge biotech enterprise that fuses computational modeling, biological automation, and exclusive data resources to optimize the development of small and large molecule therapies. Its system merges computer simulations, sequencing-derived biological proxies, and verified biological assays within a fully automated laboratory setting, facilitating swift design, production, and evaluation of new drug candidates. The organization addresses numerous medical conditions such as neurological disorders, autoimmune conditions, infectious diseases, and oncology, substantially shortening development periods and expenses relative to conventional approaches.
Key Features:
• Comprehensive Data Fusion: Integrates computational, proxy biological, and validated biological information to improve drug candidate design and verification
• Robotic Laboratory Infrastructure: Employs automated wet lab systems for high-volume synthesis and testing, speeding up iterative drug development processes
• Dual Molecule Therapeutics: Facilitates the creation and refinement of both conventional small molecules and complex biologics targeting various therapeutic areas
• Broad Disease Application: Versatile platform applicable to neuroscience, autoimmune diseases, infectious pathogens, and cancer treatments
• Exclusive AI-Driven Design Systems: Utilizes proprietary AI technologies including BAGEL and SUEDE for rapid generation and screening of innovative drug candidates
Use Cases:
• Expedited Pharmaceutical Discovery: Enables biopharma firms to reduce development cycles from initial concept to viable lead compounds through AI-automation synergy
• Alternative Pain Treatments: Creates novel small molecule solutions targeting non-opioid mechanisms for chronic pain intervention
• Rapid Antiviral Development: Swift identification and confirmation of antiviral agents, evidenced by SARS-CoV-2 inhibition research
• Collaborative Research Partnerships: Provides co-discovery, co-engineering, and platform-service arrangements to enhance partner research efficiency
